560 related articles for article (PubMed ID: 15649706)
1. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
4. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
Sedaghat K; Finkelstein DI; Gundlach AL
Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193
[TBL] [Abstract][Full Text] [Related]
5. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
[TBL] [Abstract][Full Text] [Related]
6. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
7. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
[TBL] [Abstract][Full Text] [Related]
8. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.
Ding YM; Jaumotte JD; Signore AP; Zigmond MJ
J Neurochem; 2004 May; 89(3):776-87. PubMed ID: 15086533
[TBL] [Abstract][Full Text] [Related]
9. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
[TBL] [Abstract][Full Text] [Related]
10. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
[TBL] [Abstract][Full Text] [Related]
11. Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease.
Winter C; Hosmann K; Harnack D; Meissner W; Paul G; Morgenstern R; Kupsch A
Synapse; 2006 Jul; 60(1):69-80. PubMed ID: 16598703
[TBL] [Abstract][Full Text] [Related]
12. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
[TBL] [Abstract][Full Text] [Related]
13. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
14. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
Ganser C; Papazoglou A; Just L; Nikkhah G
Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
18. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE
Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.
Iczkiewicz J; Rose S; Jenner P
Exp Neurol; 2007 Sep; 207(1):95-106. PubMed ID: 17643430
[TBL] [Abstract][Full Text] [Related]
20. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
Iwata SI; Nomoto M; Fukuda T
Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
